Cutera Archives - Medical Design Sourcing

Cutera’s AviClear acne device wins FDA clearance

[Image from Cutera]Cutera (Nasdaq:CUTR) announced today that it received FDA 510(k) clearance for its AviClear acne treatment device.

Brisbane, California-based Cutera designed AviClear as a laser treatment for the safe, prescription-free reduction of existing acne, while it also demonstrates that, following use, future breakout episodes are shorter, less intense and more infrequent.

The company said in a news release that AviClear represents the only energy-based device to receive FDA 510(k) clearance for the treatment of mild, moderate and severe acne. The platform selectively targets the sebocytes and suppresses sebum production to treat acne outbreaks.

Cutera said that clinical trials showed that acne clearance results with the use of AviClear continue to improve over time, with no pain mitigation utilized or required by any clinical study participant. The company will make AviClear available to physicians throughout the U.S. over the course of 2022. Read more

Cutera jumps 12% on reported Q1 sales growth

Cutera (NSDQ:CUTR) yesterday posted first-quarter results that beat the overall consensus on Wall Street.

The Brisbane, Calif.-based company reported losses of -$359,000, or -2¢ per share, on sales of $49.668 million for the three months ended March 31, for a sales growth of 54.06% compared with Q1 2020.

Earnings per share were 20¢ ahead of The Street, where analysts were looking for sales of $39.37 million.

“I am pleased with our first-quarter results, which reflect the continued progress we have made since the onset of the COVID-19 pandemic,” CEO Dave Mowry said in a news release. “In the first quarter, we achieved broad strength across our business, driven by consistent execution from our commercial teams, strength in the skincare business, and a slow but steady improvement in our end markets. Building upon the tremendous work from our team, in 2021 we plan to continue to improve gross margins by reducing manufacturing costs; increase sales and sales …

Cutera beats The Street in Q4 results

Cutera (NSDQ:CUTR) posted fourth-quarter results that beat the consensus forecast on Wall Street.

The Brisbane, Calif.-based company reported profits of $2.2 million, or 12¢ per share, on sales of $49.9 million for the three months ended Dec. 31, 2020, for a bottom-line sales growth of 9.5% compared with Q4 2019.

Earnings per share were 12¢, 23¢ ahead of The Street, where analysts were looking for sales of $44.5 million.

“I am pleased with our overall results for the fourth quarter and by the efforts our team put forth over the entirety of 2020. Our team’s commitment to execution drove steady improvement during the second half of 2020, posting solid results despite the difficult operating environment,” CEO Dave Mowry said.

“Our focus and resiliency enabled us to make steady progress on our vital commercial and operational initiatives during 2020. As a result of these efforts, we enter 2021 well-positioned to accelerate growth and expand profitabil…